JP2018502120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502120A5 JP2018502120A5 JP2017535690A JP2017535690A JP2018502120A5 JP 2018502120 A5 JP2018502120 A5 JP 2018502120A5 JP 2017535690 A JP2017535690 A JP 2017535690A JP 2017535690 A JP2017535690 A JP 2017535690A JP 2018502120 A5 JP2018502120 A5 JP 2018502120A5
- Authority
- JP
- Japan
- Prior art keywords
- combination according
- cpi
- antigen
- binding fragment
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 88
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims description 88
- 239000000427 antigen Substances 0.000 claims description 74
- 102000038129 antigens Human genes 0.000 claims description 74
- 108091007172 antigens Proteins 0.000 claims description 74
- 239000000556 agonist Substances 0.000 claims description 64
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 62
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 62
- 102000004965 antibodies Human genes 0.000 claims description 62
- 108090001123 antibodies Proteins 0.000 claims description 62
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 50
- 102100007290 CD274 Human genes 0.000 claims description 26
- 101710012053 CD274 Proteins 0.000 claims description 26
- 102100005310 CTLA4 Human genes 0.000 claims description 26
- 101700054183 CTLA4 Proteins 0.000 claims description 26
- 102100019764 PDCD1 Human genes 0.000 claims description 26
- 108060007796 SPATA2 Proteins 0.000 claims description 26
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 206010025310 Other lymphomas Diseases 0.000 claims description 12
- 239000010753 BS 2869 Class E Substances 0.000 claims description 6
- 210000000988 Bone and Bones Anatomy 0.000 claims description 6
- 210000004556 Brain Anatomy 0.000 claims description 6
- 210000000481 Breast Anatomy 0.000 claims description 6
- 210000003679 Cervix Uteri Anatomy 0.000 claims description 6
- 210000001072 Colon Anatomy 0.000 claims description 6
- 210000003238 Esophagus Anatomy 0.000 claims description 6
- 210000003128 Head Anatomy 0.000 claims description 6
- 210000003734 Kidney Anatomy 0.000 claims description 6
- 210000004185 Liver Anatomy 0.000 claims description 6
- 210000004072 Lung Anatomy 0.000 claims description 6
- 206010025650 Malignant melanoma Diseases 0.000 claims description 6
- 210000003205 Muscles Anatomy 0.000 claims description 6
- 210000003739 Neck Anatomy 0.000 claims description 6
- 210000001672 Ovary Anatomy 0.000 claims description 6
- 210000000496 Pancreas Anatomy 0.000 claims description 6
- 210000002307 Prostate Anatomy 0.000 claims description 6
- 210000000664 Rectum Anatomy 0.000 claims description 6
- 210000003491 Skin Anatomy 0.000 claims description 6
- 210000002784 Stomach Anatomy 0.000 claims description 6
- 210000001685 Thyroid Gland Anatomy 0.000 claims description 6
- 210000003932 Urinary Bladder Anatomy 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 210000000056 organs Anatomy 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 210000001519 tissues Anatomy 0.000 claims description 6
- 101700046422 IFNA Proteins 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462098568P | 2014-12-31 | 2014-12-31 | |
US62/098,568 | 2014-12-31 | ||
US201562106526P | 2015-01-22 | 2015-01-22 | |
US62/106,526 | 2015-01-22 | ||
US201562118165P | 2015-02-19 | 2015-02-19 | |
US62/118,165 | 2015-02-19 | ||
PCT/US2015/067269 WO2016109310A1 (en) | 2014-12-31 | 2015-12-22 | Combination tumor immunotherapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020187016A Division JP2021014465A (ja) | 2014-12-31 | 2020-11-10 | 組合せ腫瘍免疫療法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018502120A JP2018502120A (ja) | 2018-01-25 |
JP2018502120A5 true JP2018502120A5 (US07794700-20100914-C00152.png) | 2019-02-14 |
JP6885867B2 JP6885867B2 (ja) | 2021-06-16 |
Family
ID=56284932
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017535690A Active JP6885867B2 (ja) | 2014-12-31 | 2015-12-22 | 組合せ腫瘍免疫療法 |
JP2020187016A Withdrawn JP2021014465A (ja) | 2014-12-31 | 2020-11-10 | 組合せ腫瘍免疫療法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020187016A Withdrawn JP2021014465A (ja) | 2014-12-31 | 2020-11-10 | 組合せ腫瘍免疫療法 |
Country Status (21)
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200030375A1 (en) * | 2012-06-27 | 2020-01-30 | Kenichiro Hasumi | Therapy and methods of introducing immature dendritic cells and/or cytoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors |
DK2992017T3 (da) | 2013-05-02 | 2021-01-25 | Anaptysbio Inc | Antistoffer rettet mod programmeret død-1 (pd-1) |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
DK3081576T3 (da) | 2013-12-12 | 2019-10-21 | Shanghai hengrui pharmaceutical co ltd | Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf |
WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
AU2016271018A1 (en) | 2015-05-29 | 2017-11-30 | Dynavax Technologies Corporation | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer |
CN108368170B (zh) | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
ES2939534T3 (es) * | 2015-08-06 | 2023-04-24 | Univ Minnesota | Activación moduladora de inflamasomas de células supresoras derivadas de mieloides para tratar EICH |
GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
US10358496B2 (en) | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
WO2017173334A1 (en) * | 2016-04-01 | 2017-10-05 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与 |
BR112019008859A2 (pt) | 2016-11-01 | 2019-07-09 | Anaptysbio Inc | anticorpos direcionados contra a morte programada 1 (pd-1) |
CN110072553B (zh) * | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
EP3603668A4 (en) * | 2017-03-29 | 2021-01-06 | Terumo Kabushiki Kaisha | ADDITIVE COMPOSITION, VACCINE COMPOSITION AND MEDICINAL KIT WITH IT |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
US20210030783A1 (en) * | 2018-02-13 | 2021-02-04 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
WO2019200238A1 (en) | 2018-04-14 | 2019-10-17 | Dynavax Technologies Corporation | Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer |
CN108486120B (zh) * | 2018-04-28 | 2019-12-06 | 新乡医学院 | 一种新型CpG ODN序列及其在抗黑色素瘤上的应用 |
EP3566718A1 (en) * | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
JP7359785B2 (ja) * | 2018-06-05 | 2023-10-11 | 江蘇康寧杰瑞生物制薬有限公司 | 二量体及びその使用 |
WO2020081398A1 (en) * | 2018-10-14 | 2020-04-23 | Dynavax Technologies Corporation | Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer |
CA3116733A1 (en) * | 2018-10-18 | 2020-04-23 | Idera Pharmaceuticals, Inc. | Tlr9 modulators for treating cancer |
EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
CN113122541A (zh) * | 2019-12-31 | 2021-07-16 | 财团法人工业技术研究院 | 核酸药物复合体以及其用途 |
WO2022110010A1 (zh) * | 2020-11-27 | 2022-06-02 | 苏州吉玛基因股份有限公司 | 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用 |
CN114099535B (zh) * | 2020-12-10 | 2023-01-03 | 南京吉迈生物技术有限公司 | Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物 |
WO2023096934A1 (en) * | 2021-11-24 | 2023-06-01 | Wisconsin Alumni Research Foundation | Nanoparticles for potentiating effects of radiation therapy on anti-cancer immunotherapy |
WO2023130072A1 (en) | 2022-01-03 | 2023-07-06 | Checkmate Pharmaceuticals, Inc. | Transcriptional biomarkers for response to innate immune activators |
CN114982711B (zh) * | 2022-05-30 | 2023-11-10 | 广东省人民医院 | 小鼠胃间质瘤自发成瘤模型及其构建方法和应用 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
JP2547714B2 (ja) | 1981-10-23 | 1996-10-23 | モルキユラ− バイオシステムズ インコ−ポレテツド | オリゴヌクレオチド治療剤及びその製法 |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU661854B2 (en) | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
US5859231A (en) | 1993-09-03 | 1999-01-12 | Duke University | Synthesis of oligonucleotides with boranophosphonate linkages |
US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE328890T1 (de) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
US20020088014A1 (en) | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
DE19826758C1 (de) | 1998-06-15 | 1999-10-21 | Soft Gene Gmbh | Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte |
JP2002521489A (ja) | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | CpGオリゴヌクレオチドの立体異性体および関連する方法 |
AR020848A1 (es) | 1998-10-23 | 2002-05-29 | Amgen Inc | Metodos y composiciones para la prevencion y el tratamiento de anemia |
DE69938871D1 (de) | 1998-12-03 | 2008-07-17 | Univ California | Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US6207819B1 (en) | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
CA2381770C (en) | 1999-08-24 | 2007-08-07 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
PT1274728E (pt) | 2000-04-21 | 2008-06-20 | Amgen Inc | Métodos e composições para a prevenção e tratamento de anemia |
EP2011802A3 (en) | 2001-04-27 | 2009-04-15 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
EP1446162B1 (en) | 2001-08-17 | 2008-10-15 | Coley Pharmaceutical GmbH | Combination motif immune stimulatory oligonucleotides with improved activity |
ATE447967T1 (de) * | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
SG159381A1 (en) | 2001-10-10 | 2010-03-30 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
JP4409430B2 (ja) | 2002-07-03 | 2010-02-03 | 小野薬品工業株式会社 | 免疫賦活組成物 |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
CN100560719C (zh) | 2003-03-26 | 2009-11-18 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
EP1699480B1 (de) | 2003-12-30 | 2011-06-15 | Mologen AG | Allogenes tumortherapeutikum |
CN1918293A (zh) | 2004-02-20 | 2007-02-21 | 莫洛根股份公司 | 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子 |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
MX2008000379A (es) | 2005-07-07 | 2008-03-18 | Coley Pharm Group Inc | Anticuerpo anti-citla-1 y terapia de combinacio con oligodesoxinucleotido sintetico que contiene motivo cpg. |
EP1963502A4 (en) | 2005-11-11 | 2010-04-07 | Pfizer | COMBINATIONS AND METHOD FOR USE OF AN IMMUNOMODULATIVE OLIGODESOXYNUCLEOTIDE |
EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
US20080045473A1 (en) | 2006-02-15 | 2008-02-21 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
CN101479375B (zh) * | 2006-05-03 | 2016-03-30 | 科罗拉多州立大学董事会 | Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途 |
CA2655108C (en) | 2006-06-12 | 2019-05-07 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
PT2078080E (pt) | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
EP2125854B1 (en) | 2006-12-12 | 2016-10-26 | Kuros Biosciences AG | Oligonucleotides containing high concentrations of guanine monomers |
WO2009022215A1 (en) | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
WO2012006634A2 (en) * | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
KR20200075023A (ko) * | 2012-05-04 | 2020-06-25 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
US9719791B2 (en) | 2014-12-10 | 2017-08-01 | Mapquest, Inc. | Computerized systems and methods for providing travel information and/or content to users |
AU2016271018A1 (en) * | 2015-05-29 | 2017-11-30 | Dynavax Technologies Corporation | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer |
US9917100B2 (en) | 2015-11-20 | 2018-03-13 | Sandisk Technologies Llc | Three-dimensional NAND device containing support pedestal structures for a buried source line and method of making the same |
ITUA20162720A1 (it) | 2016-04-19 | 2017-10-19 | Risco Spa | Apparecchiatura per preparare un prodotto alimentare |
-
2015
- 2015-12-22 LT LTEP15876030.6T patent/LT3240801T/lt unknown
- 2015-12-22 PT PT158760306T patent/PT3240801T/pt unknown
- 2015-12-22 NZ NZ734144A patent/NZ734144A/en unknown
- 2015-12-22 RS RS20210195A patent/RS61470B1/sr unknown
- 2015-12-22 EP EP21151085.4A patent/EP3835312A1/en active Pending
- 2015-12-22 DK DK15876030.6T patent/DK3240801T3/da active
- 2015-12-22 WO PCT/US2015/067269 patent/WO2016109310A1/en active Application Filing
- 2015-12-22 ES ES15876030T patent/ES2856844T3/es active Active
- 2015-12-22 CN CN201580075681.0A patent/CN107428813B/zh active Active
- 2015-12-22 CN CN202110797632.5A patent/CN113813386A/zh active Pending
- 2015-12-22 EP EP15876030.6A patent/EP3240801B1/en active Active
- 2015-12-22 SI SI201531505T patent/SI3240801T1/sl unknown
- 2015-12-22 HU HUE15876030A patent/HUE053145T2/hu unknown
- 2015-12-22 AU AU2015374385A patent/AU2015374385B2/en active Active
- 2015-12-22 PL PL15876030T patent/PL3240801T3/pl unknown
- 2015-12-22 MX MX2017008658A patent/MX2017008658A/es unknown
- 2015-12-22 CA CA2972757A patent/CA2972757A1/en active Pending
- 2015-12-22 US US15/540,913 patent/US10682365B2/en active Active
- 2015-12-22 JP JP2017535690A patent/JP6885867B2/ja active Active
-
2017
- 2017-06-28 MX MX2022008338A patent/MX2022008338A/es unknown
-
2018
- 2018-05-04 HK HK18105759.0A patent/HK1246319A1/zh unknown
-
2020
- 2020-05-05 US US16/867,296 patent/US20200281953A1/en active Pending
- 2020-08-20 ZA ZA2020/05298A patent/ZA202005298B/en unknown
- 2020-08-26 AU AU2020223671A patent/AU2020223671C1/en active Active
- 2020-11-10 JP JP2020187016A patent/JP2021014465A/ja not_active Withdrawn
-
2021
- 2021-02-04 HR HRP20210200TT patent/HRP20210200T1/hr unknown
- 2021-02-16 CY CY20211100130T patent/CY1123868T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018502120A5 (US07794700-20100914-C00152.png) | ||
HRP20210200T1 (hr) | Kombinirana antitumorska imunoterapija | |
Abbott et al. | Cancer and the immune system: the history and background of immunotherapy | |
Hu et al. | The abscopal effect of radiation therapy: what is it and how can we use it in breast cancer? | |
JP2016536286A5 (US07794700-20100914-C00152.png) | ||
HRP20190774T1 (hr) | Kombinacija anti-lag-3 antitijela i anti-pd-1 antitijela za liječenje tumora | |
Borg et al. | Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study | |
JP2017516775A5 (US07794700-20100914-C00152.png) | ||
RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
RU2017117664A (ru) | Комбинация | |
JP2015532292A5 (US07794700-20100914-C00152.png) | ||
JP2015534577A5 (US07794700-20100914-C00152.png) | ||
AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
MX2021008224A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
JP2019532047A5 (US07794700-20100914-C00152.png) | ||
JP2016540042A5 (US07794700-20100914-C00152.png) | ||
MX2016010683A (es) | Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2. | |
JP2019504105A5 (US07794700-20100914-C00152.png) | ||
JP2017538680A5 (US07794700-20100914-C00152.png) | ||
MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
JP2016183163A5 (US07794700-20100914-C00152.png) | ||
Feng et al. | Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma | |
JP2018509423A5 (US07794700-20100914-C00152.png) |